Alpine Immune Sciences Presents New Preclinical Data at 2020 Crohn’s & Colitis Congress ALPN-101 efficacious in a preclinical model of inflammatory bowel disease
SEATTLE, WA, January 24, 2020 – Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, presented new preclinical data on its lead program, ALPN-101, at the 2020 Crohn’s & Colitis Congress in Austin, Texas.
In the poster titled, “ALPN-101, A First-In-Class Dual ICOS/CD28 Antagonist, Demonstrates Efficacy in Patient-Derived PBMC In Vitro and in an In Vivo T Cell Transfer Model of Chronic Inflammatory Bowel Disease (IBD),” ALPN-101 modulated inflammatory cytokines in vitro from human IBD peripheral blood mononuclear cells (PBMC) more potently than CD28 or ICOS single-pathway inhibitors. In addition, it significantly reduced disease activity in the CD4+CD45RBhi T cell transfer mouse colitis model.
“This new data further adds to the future development options for ALPN-101, which has already demonstrated differentiated activity in some preclinical models of graft-versus-host disease and rheumatic diseases,” commented Stanford Peng, MD PhD, President and Head of Research and Development at Alpine. “Now that our first-in-human study in healthy volunteers has been completed, we look forward to clinical trials in such diseases.”
The full poster presentation can be found at alpineimmunesciences.com, at this (LINK).
ALPN-101 is a novel Fc fusion protein of a human inducible T cell costimulator ligand (ICOSL) variant immunoglobulin domain (vIgD™), a first-in-class therapeutic designed to inhibit simultaneously the CD28 and ICOS inflammation pathways. CD28 and ICOS are closely related costimulatory molecules with partially overlapping roles in T cell activation likely playing a role in multiple autoimmune and inflammatory diseases. In preclinical models of graft versus host disease, inflammatory arthritis, connective tissue disease, and multiple sclerosis, ALPN-101 demonstrates efficacy superior to agents blocking the CD28 – CD80/86 and/or ICOS - ICOSL pathways alone.
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics, creating potentially powerful multifunctional immunotherapies to improve patients’ lives via unique protein engineering technologies. Alpine has two lead programs. The first, ALPN-101 for autoimmune/inflammatory diseases, is a selective dual T cell costimulation blocker engineered to reduce pathogenic T and B cell immune responses by blocking ICOS and CD28. ALPN-101 has recently completed enrollment in a Phase 1 healthy volunteer trial. The second, ALPN-202 for cancer, is a conditional CD28 costimulator and dual checkpoint inhibitor. Alpine is backed by world-class research and development capabilities, a highly productive scientific platform, and a proven management team. For more information, visit www.alpineimmunesciences.com.
Courtney Dugan, 212-257-6723
Sheryl Seapy, 213-262-9390